Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 7/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24392666 | 0.82 | ALDH1A1 (0.33) | ALDH1A1EGFRKDRKDM4EPKM | |
| SCHEMBL24392462 | 0.81 | ALDH1A1 (0.43) | ALDH1A1EGFRKDRKDM4EPKM | |
| SCHEMBL24393049 | 0.81 | ALDH1A1 (0.35) | ALDH1A1EGLN2ALOX15TSHRMAPK1 | |
| SCHEMBL24392619 | 0.79 | EGLN2 (0.35) | ALDH1A1EGFRKDREGLN2ALOX15 | |
| SCHEMBL24393338 | 0.79 | ALDH1A1 (0.33) | ALDH1A1EGFRKDRKDM4EPKM | |
| SCHEMBL24391780 | 0.76 | ACVRL1 (0.33) | ALDH1A1EGLN2ALOX15TSHRMAPK1 | |
| SCHEMBL24391967 | 0.75 | EGLN2 (0.37) | EGLN2 | |
| SCHEMBL24392206 | 0.66 | ALDH1A1 (0.31) | ALDH1A1KDM4E | |
| SCHEMBL24392052 | 0.63 | ALDH1A1 (0.35) | ALDH1A1EGLN2KDM4EPKMENPP1 | |
| SCHEMBL24393212 | 0.63 | ALDH1A1 (0.35) | ALDH1A1EGLN2TSHRKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | ALDH1A1 754/4885EGFR 4503/4885KDR 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.